Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04105335
Title A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mina Alpha Limited

peritoneum cancer

pancreatic cancer

Advanced Solid Tumor

fallopian tube cancer

ovarian cancer


CEBPA-51 + Pembrolizumab

Age Groups: senior | adult
Covered Countries

No variant requirements are available.